Go Pro
NASDAQ:ZYBT

Zhengye Biotechnology Q4 2025 Earnings Report

Zhengye Biotechnology logo
$1.56 +0.03 (+1.96%)
Closing price 04:00 PM Eastern
Extended Trading
$1.56 +0.00 (+0.32%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zhengye Biotechnology EPS Results

Actual EPS
-$0.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Zhengye Biotechnology Revenue Results

Actual Revenue
$3.97 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zhengye Biotechnology Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Zhengye Biotechnology Earnings Headlines

Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, a sign of where AI infrastructure spending is heading next. Anthropic remains private, but one publicly traded vehicle holds it as its largest position, alongside stakes in Databricks and Anduril. It trades through any standard brokerage account.tc pixel
See More Zhengye Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zhengye Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zhengye Biotechnology and other key companies, straight to your email.

About Zhengye Biotechnology

Zhengye Biotechnology (NASDAQ:ZYBT) is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

View Zhengye Biotechnology Profile